MS is a common disease in young adults but rare in children. More than a dozen treatments have been approved by the US Food and Drug Administration for treating MS in adults, and several of these treatments are prescribed in children. However, high-quality targeted evidence for children has been lacking. A recent phase III double-blind randomised controlled trial of fingolimod (PARADIGMS) versus interferon beta-1a was the first to show that fingolimod significantly reduced the relapse rate by 82% and the appearance of new or enlarging lesions on T2-weighted MRI by 53%. These benefits came at the cost of more serious adverse events in children with …

中文翻译：

---

儿童多发性硬化症的首批批准治疗减缓脑萎缩

MS是年轻人中的常见疾病，但在儿童中很少见。美国食品药品监督管理局已经批准了十几种用于成人MS的治疗方法，其中一些用于儿童。但是，缺乏针对儿童的高质量针对性证据。芬戈莫德与干扰素β-1a的最新III期双盲随机对照试验首次表明，芬戈莫德可显着降低复发率82％，T2加权MRI上新出现的或扩大的病灶可减少53％ ％。这些好处是以患有……的儿童更严重的不良事件为代价的。